What's on Reshma Kewalramani's mind?
sized by share of brain — tap one to pop it open · "everything else" is the back of her mind, up close
Vertex posts a strong Q2 and raises the 2026 revenue bar
The quarter landed well enough that she moved the full-year number up rather than sitting on the beat.
Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal
The Business Journals · 2026-08-04raising guidance in august is a confidence signal you can't walk back quietly. she'd rather set a higher bar in public than let anyone price vertex as a one-drug company coasting on trikafta.
how sure? very sure · see the 2 sources
Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal
The Business Journals · 2026-08-04Vertex posts strong 2nd-qtr 2026 results
The Pharma Letter · 2026-08-04CEO spends earnings day defending the $10 billion Crinetics logic
She used the guidance raise as the stage to explain what ten billion dollars actually buys.
Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal
The Business Journals · 2026-08-04the deal is done, so now the job is narrative maintenance. touting benefits on an earnings call is how you keep a big check from being re-litigated every quarter by people who already voted with their sell button.
how sure? very sure · see the 1 source
Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal
The Business Journals · 2026-08-04Vertex says it's unfazed as an IgAN decision looms in a crowded field
The kidney-disease space is filling up fast, and the FDA verdict is the next thing on the calendar she can't control.
Vertex unfazed by competitive IgAN space as FDA verdict looms
BioSpace · 2026-08-04saying 'unfazed' out loud is what you do when everyone can see the competitors. the real bet is that approval plus vertex's launch machinery beats being first into a market that's already elbows-out.
how sure? pretty sure · see the 1 source
Vertex unfazed by competitive IgAN space as FDA verdict looms
BioSpace · 2026-08-04Every headline she wants is about a drug that isn't for cystic fibrosis
Guidance, an acquisition and a pending approval are all arguments that Vertex is more than its CF book.
Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal
The Business Journals · 2026-08-04cf still pays for everything, and that's exactly the problem. the whole point of a $10b deal and a kidney filing is to make the next investor question be about something other than trikafta's patent cliff.
how sure? pretty sure · see the 1 source
Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal
The Business Journals · 2026-08-04Vertex posts a strong Q2 and raises the 2026 revenue bar
The quarter landed well enough that she moved the full-year number up rather than sitting on the beat.
Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal
The Business Journals · 2026-08-04raising guidance in august is a confidence signal you can't walk back quietly. she'd rather set a higher bar in public than let anyone price vertex as a one-drug company coasting on trikafta.
Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal
news.google.com · 2026-08-05every line on the pad traces to something public — tap to see it
Vertex unfazed by competitive IgAN space as FDA verdict looms
news.google.com · 2026-08-05every line on the pad traces to something public — tap to see it
Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal
news.google.com · 2026-08-05every line on the pad traces to something public — tap to see it
Vertex posts strong 2nd-qtr 2026 results
news.google.com · 2026-08-05every line on the pad traces to something public — tap to see it
the other 19% — quieter, but still in there19%
Defending the cystic fibrosis book
the franchise that funds the diversification still has to hold its numbers every single quarter, quietly, while everyone talks about the new stuff.
Vertex posts strong 2nd-qtr 2026 results
The Pharma Letter · 2026-08-04Non-opioid pain launch
a first-in-class painkiller only counts once payers cover it, so the launch curve gets checked more often than she'd admit.
Vertex posts strong 2nd-qtr 2026 results
The Pharma Letter · 2026-08-04Casgevy patient throughput
a curative gene edit is a miracle that still moves one patient at a time through one authorized center at a time.
Vertex posts strong 2nd-qtr 2026 results
The Pharma Letter · 2026-08-04Keeping the pipeline honest
buying growth is faster than growing it; the internal programs still have to prove they were worth the r&d line.
Vertex unfazed by competitive IgAN space as FDA verdict looms
BioSpace · 2026-08-04Type 1 diabetes cell therapy
the islet cell program is the moonshot she gets asked about at every conference, whether or not there's news.
Pricing politics
raising revenue guidance in an election-adjacent year is the kind of good news that invites the wrong kind of hearing invitation.